Cure for Cade UPDATE

Cade was diagnosed with hereditary spastic paraplegia. Cade's mom, Emma joins Capital Chat to share the news that Cade was selected for the clinical trial of gene therapy for SPG50. The family will be in Texas for the next 2 to 3 months.

Cade Jobsis, a young boy from Juneau, Alaska, is receiving a, groundbreaking gene therapy for his rare genetic condition, AP4 Hereditary Spastic Paraplegia (SPG50). Following massive local support and over $1 million raised toward the funding of the clinical trial.

SPG50 is an ultra-rare, degenerative, neurodegenerative disease that leads to the loss of motor and cognitive function. A specially developed, single-injection gene therapy is used to target and correct the genetic mutation. The Juneau community and donors contributed over $1 million in 2025 to fund the clinical trial, with significant fundraising efforts from his family,